Vitamin D, a hormone involved in bone and calcium homeostasis, has been shown to have potent immunomodulatory effects. We performed a retrospective cohort analysis to evaluate whether monohydroxyvitamin D levels before allogeneic hematopoietic SCT (HSCT) correlate with the risk of GVHD. Fifty-three patients who underwent myeloablative HSCT were studied. Vitamin D levels were measured in serum samples obtained before HSCT. The median 25-hydroxyvitamin vitamin D level was 21.9 ng/mL (7.8-45.7). The cumulative incidence (CI) of grades II-IV acute GVHD at 100 days was 53.1% in patients with vitamin Do25, versus 33.3% in patients with vitamin DX25 ng/mL (P ¼ 0.13). The CI of chronic GVHD (cGVHD) at 2 years in patients with vitamin Do25 was 63.8%, compared with 23.8% in patients with vitamin DX25 ng/mL (P ¼ 0.009). Similarly, the 2 year CI of extensive cGVHD was significantly greater in patients with vitamin Do25 compared with those with vitamin DX25 ng/mL (54.5% versus 14.3%, P ¼ 0.005). In a multivariable competing risk model, low pre-transplant vitamin D levels remained a significant factor associated with cGVHD (hazard ratio ¼ 5.26, P ¼ 0.02). Our results demonstrate that vitamin D deficiency before HSCT is associated with an increased risk of cGVHD. (2013) 48, 593-597; doi:10.1038/bmt.2012 published online 24 September 2012 Keywords: Vitamin D; GVHD; hematopoietic SCT INTRODUCTION GVHD remains a significant cause of morbidity and mortality following allogeneic HSCT. Despite standard immune-suppression with a calcineurin inhibitor and MTX, grade II-IV acute GVHD rates range from 20-50% and chronic GVHD from 40-50% after BMT.
INTRODUCTION
GVHD remains a significant cause of morbidity and mortality following allogeneic HSCT. Despite standard immune-suppression with a calcineurin inhibitor and MTX, grade II-IV acute GVHD rates range from 20-50% and chronic GVHD from 40-50% after BMT. [1] [2] [3] Therefore, a strategy that decreases the incidence of GVHD is critical toward improving outcomes following HSCT.
GVHD is mediated by the activation and expansion of donor derived alloreactive lymphocytes stimulated in part by residual host DCs and donor DCs with cross presentation of alloantigens. 4, 5 Strategies that bias toward tolerizing DCs during the period of alloreactive sensitization hold promise as a novel approach to prevent GVHD. Vitamin D is a hormone involved in bone metabolism and calcium homeostasis that has been shown to have a significant role in the regulation of host immune responses and the prevention of autoimmunity. In animal models, vitamin D has been shown to reduce airway inflammation in a rat asthma model, 6 and suppress or prevent autoimmune encephalomyelitis, 7 arthritis, 8 inflammatory bowel disease 9, 10 and diabetes. 11 In addition, it has been shown that patients with systemic lupus erythematosus, Behcets Disease, Type 1 diabetes mellitus, and multiple sclerosis have low levels of vitamin D. [12] [13] [14] [15] [16] [17] The impact of vitamin D on host immunity is mediated, in part, by its effect on DCs. In one study, vitamin D was shown to exert an immunomodulatory effect on myeloid DCs, suppressing Th1 responses. 18 Vitamin D inhibits the maturation of DCs, resulting in the accumulation of immature DCs with a potentially immunosuppressive phenotype. [19] [20] [21] [22] [23] In a murine model, addition of 1a25 hydroxyvitamin D 3 to BM cells cultured in the presence of GM-CSF, and IL-4 resulted in lower levels of CD80 and CD86 expression, and decreased IL-12 secretion. In this model, pre-treatment of female mice with DCs derived from male donors and generated in the presence of vitamin D enabled the engraftment of male skin grafts to female hosts. 24 In a vitamin D receptor knock-out mouse model, it has been demonstrated that vitamin D-mediated suppression of DC maturation was lost resulting in the increased capacity to stimulate allogeneic T-cell proliferation. 20 DCs generated in the presence of vitamin D demonstrate impaired secretion of IL-12 and induce hyporesponsiveness of allogeneic T cells. 22, 25 Vitamin D has also been shown to enhance apoptosis of mature DCs resulting in inhibition of T-cell alloreactivity. 21 Taken together, these data suggest that vitamin D may inhibit DC-mediated expansion of alloreactive T cells, and that vitamin D deficiency could potentially be a risk factor for the development of GVHD after allogeneic HSCT. To investigate this hypothesis, we performed a retrospective cohort study to evaluate whether monohydroxyvitamin D levels measured in serum samples obtained from patients before allogeneic transplantation were predictive of the development of GVHD. 
MATERIALS AND METHODS

Fifty
Statistical Analyses
The Wilcoxon rank-sum test, w 2 -test, or Fisher's exact test was used for two sample comparisons. All tests were two-sided. To establish a cutoff value for the predictive level of vitamin D, analysis of the receiver operator characteristic curve was performed. Cumulative incidence (CI) curves for relapse and both acute and chronic GVHD were constructed reflecting time to relapse and time to either acute or chronic GVHD as competing risks. The difference between CI curves in the presence of a competing risk was tested using the Gray method. 26 OS and PFS were calculated using the Kaplan-Meier method. The Log-rank test was used for comparisons of Kaplan-Meier curves. Prognostic factors for relapse and chronic GVHD were examined in competing risks regression analysis. All analyses were performed using SAS v 9.2 and R v 2.10.1.
RESULTS
Fifty-three patients were identified who underwent a myeloablative allogeneic HSCT, and who had pre-transplant serum samples cryopreserved. The median age was 44 years (range 19-57). Fifty-eight percent of patients were male. GVHD prophylaxis consisted of tacrolimus (target trough 5-10 ng/mL) and MTX with the addition of sirolimus for two patients. Tapering of immune-suppression began by day 100 and was complete by 6 months in all the patients who did not have evidence of GVHD. Thirty-three patients received stem cells from a matched related donor, while 20 patients received stem cells from an unrelated donor. All patients had a 6/6 HLA match. The median 25-OH vitamin D level was 21.9 ng/mL (range 7.8-45.7). Of the 53 patients, 13 (24.5%) received a standard multivitamin. Five of 53 patients (9%) received vitamin D supplementation (200-400 IU) combined with calcium supplements. Notably, all of the patients who took a multivitamin alone or multivitamin þ calcium þ vitamin D supplementation had vitamin D levels 430 ng/mL.
Patients were divided into two cohorts based on a vitamin D level: o25 ng/mL (32 patients) or X25 ng/mL (21 patients). Albumin levels were measured as an assessment of nutritional status. The median albumin level was 3.9 g/dL (range 2.6-4.9) and was not significantly different between the two groups (P ¼ 0.16). Patient demographics are summarized in Table 1 . There was no difference between the groups with respect to patient or donor age, donor type (matched related versus unrelated donor), cell source (peripheral blood versus BM), patient/donor CMV status, conditioning regimen, or GVHD prophylaxis regimen.
GVHD
The CI of grades II-IV acute GVHD at 100 days was 53.1% in the group with vitamin D level o25 ng/mL versus 33.3% in the group with vitamin DX25 ng/mL (P ¼ 0.13). Remarkably, the CI of chronic GVHD (cGVHD) at 2 years in patients with 25-OH vitamin D o25 ng/mL was 63.8%, compared with 23.8% in patients with vitamin D levelsX25 ng/mL (P ¼ 0.009). Figure 1 represents the CI of cGVHD with death and relapse as a competing risk. Similarly, the 2 year CI of extensive cGVHD was significantly higher in patients with vitamin D levels o25 ng/mL compared with those with X25 ng/mL (54.5% versus 14.3%, P ¼ 0.005). Figure 2 represents the CI of extensive cGVHD with death and relapse as a competing risk. Of the patients who developed cGVHD 14 or 63.6% had preceding acute GVHD.
In a multivariable competing risk model adjusted for prior transplant, patient age and patient-donor gender with relapse and death as competing risks, low pretransplant vitamin D level remained OS and PFS Three-year PFS and OS were similar between the two groups. Three year PFS was 51% in patients with vitamin D level o25 ng/mL versus 47% in patients with vitamin D level X25 ng/mL (P ¼ 0.61, Figure 3a) . The OS was 53% and 50% in patients with vitamin D levels of o25 ng/mL and X25 ng/mL, respectively (P ¼ 0.57, Figure 3b ).
DISCUSSION
In this retrospective cohort study, we have demonstrated that vitamin D deficiency before allogeneic transplantation is associated with a significantly increased risk of chronic GVHD. While there is no consensus for optimal vitamin D levels, for this analysis vitamin D deficiency was defined as a level o25, based on literature where levels ranging from 20-30 have been used to Progression-free survival VitD<25 vs. VitD>=25 P =0.61
VitD<25 vs. VitD>=25 P =0.57 Figure 3 . (a) and (b) PFS and OS. Three years PFS was 51% in patients with vitamin D level o25 ng/mL versus 47% in patients with vitamin D level equal to 25 ng/mL (P ¼ 0.61, a). The OS was 53 and 50% in patients with vitamin D levels of o25 ng/mL and equal to 25 ng/mL, respectively (P ¼ 0.57, b).
define deficient levels. 27, 28 Our findings appear to be in keeping with results published in renal and liver transplantation, where low vitamin D levels have been associated with an increased risk of rejection of transplanted organs. 29, 30 In renal transplant recipients, patients receiving vitamin D supplementation had a significant reduction in acute rejection episodes and graft loss. 31 Conversely, vitamin D deficiency has been associated with an increase in allo-reactive T cells in patients undergoing hemodialysis. 32 In heart transplant recipients, the use of oral calcitriol has been associated with lower CYA use in retrospective studies. 33 GVHD is mediated by donor derived alloreactive lymphocytes, which are stimulated both by residual host DCs, and by donor DCs with cross presentation of alloantigens. Vitamin D has been shown to interfere with DC maturation in vitro, and impairs the allostimulatory capacity of DCs. [20] [21] [22] [23] [34] [35] [36] DCs generated ex-vivo in the presence of vitamin D express increased levels of PD-L1, a negative regulator of activated T-cell responses, 37 and induce regulatory T-cell populations. In animal models, vitamin D has been shown to prolong survival of liver, renal and cardiac allografts. 11, 34, [38] [39] [40] [41] Topical treatment with vitamin D has been shown to decrease the allo-stimulatory capacity of DCs in the skindraining lymph nodes, and enhanced the suppressive capacity of regulatory T cells. 42 The growing in vitro and animal literature demonstrating the effects of vitamin D on DC and T-cell populations support the hypothesis that vitamin D has a role in modulating GVHD.
Lack of sun exposure, poor absorption, suboptimal dietary intake of vitamin D, and the use of immunosuppressant medications, [43] [44] [45] [46] likely contribute to the insufficient levels observed in this cohort of transplant patients. 34 Several recent publications have demonstrated that vitamin D deficiency is common in allogeneic transplant patients. In a retrospective study at MD Anderson, the median vitamin D level in patients undergoing transplantation was 16 ng/mL, with 70% of patients being vitamin D deficient. 47 Similarly, Urbain et al. 48 recently reported that in a cohort of allogeneic transplant patients, 25 hydroxyvitamin D concentrations were 16.4 ± 8.9 ng/mL, with 89% of patients having deficient levels. In a study of 289 adult patients with AML or ALL undergoing allogeneic SCT at Cleveland Clinic, 89.7% of patients were found to have vitamin D levels o30 ng/mL post transplant. Conversely, Robien et al. 49 demonstrated that in a cohort of allogeneic transplant patients, most patients had vitamin D levels greater than 30 ng/mL. In contrast to our study, all of the patients in the cohort published by Robien, et al. were assessed more than 1 year following transplantation, and most were on vitamin D supplementation post-transplantation. GVHD incidence was not assessed, although an inverse correlation between prednisone use and vitamin D levels was observed.
Notably, a recent study demonstrated that in 12 patients with chronic GVHD who were initiated on vitamin D therapy for osteopenia or osteoporosis, 11 patients demonstrated improvement in their manifestations of GVHD (five complete response, six partial response) after 6 months of therapy. Importantly, in this publication, 50% of patients who received vitamin D for osteopenia or osteoporosis following allogeneic transplantation were off immunosuppression at 6 months, compared with 20% in patients who did not receive vitamin D. 50 The effect of vitamin D supplementation on transplant outcome is a critical question that requires evaluation in a prospective clinical trial.
Limitations of this study include the retrospective design and small number of patients for whom pre-transplant cryopreserved serum samples were available for measurement of vitamin D levels. Nonetheless, the finding of a statistically significant difference in the incidence of chronic GVHD in patients with low vitamin D level is of interest, and has the potential to alter treatment for patients undergoing allogeneic transplantation. The results provide basis to investigate vitamin D deficiency as a risk factor for GVHD in registry studies, and the use of vitamin D as a supplement to standard of care treatment and/ or prophylaxis of GVHD in prospective clinical trials.
In summary, in this retrospective study, we demonstrate that low levels of vitamin D are associated with an increased incidence of chronic GVHD. There is an increasing literature to support the effect of vitamin D on T-cell and DC populations in vitro, and on promoting tolerance in animal models. Similarly, retrospective data in solid organ transplantation supports both the correlation between low levels of vitamin D and graft rejection, and the improvement in transplant outcome with vitamin D supplementation. Our results should stimulate further investigation into the association between vitamin D and chronic GVHD, perhaps in registry and/or prospective clinical trials. A clinical trial evaluating the effect of pre and post transplant vitamin D supplementation on GVHD is planned.
